{
    "Clinical Trial ID": "NCT00612560",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm A - Flaxseed & Active Anastrazole",
        "  25 mg flaxseed per day and 1 mg anastrozole pill per day",
        "  Anastrozole: 1 mg per day",
        "  flaxseed: 25 g per day ground",
        "INTERVENTION 2: ",
        "  Arm B - Flaxseed",
        "  Flaxseed 25 mg per day and 1 placebo pill per day",
        "  flaxseed: 25 g per day ground"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Age  18 and  85 years",
        "  Postmenopausal status defined as: no menstrual cycle in the past 12 months hysterectomy with bilateral oophorectomy hysterectomy with intact ovaries if age > 55 years",
        "  Newly diagnosed with incident, primary, invasive, estrogen receptor positive clinical stage II or lower breast cancer",
        "  ECOG performance status of 1 or less",
        "  Willingness to comply with study guidelines and procedures",
        "  Willingness and ability to provide informed consent",
        "  Usual consumption of soy no more than 1 time per week and willingness to avoid whole soy foods or concentrated soy sources (soy milk, tofu, substitute meat products, meal replacement bars) during the intervention period",
        "  Willingness to avoid herbal and dietary supplements (not including vitamins), aspirin, and ibuprofen during the intervention period",
        "  No competing neoadjuvant or chemotherapy treatment",
        "  Time between pre-surgical visit and surgery must be at least 2 weeks",
        "  No chemotherapy in the past 12 months",
        "Exclusion Criteria:",
        "  Inability to read and write English",
        "  Previous invasive breast cancer",
        "  Insulin dependent Type I or II diabetes diagnosed by physician",
        "  History of coagulopathy, thrombocytopenia, or bleeding disorder",
        "  Current (past 30 days) regular (at least once per week) use of reproductive hormone therapy, Tamoxifen, aromatase inhibitors, or other estrogen inhibitors, flaxseed, or antibiotics",
        "  Current chemotherapy or neoadjuvant chemotherapy",
        "  Allergies to flaxseed, nuts, or other seeds",
        "  Renal dysfunction defined as creatinine > 1.5 mg/dl",
        "  History of Crohns' disease, ulcerative colitis, irritable bowel syndrome, celiac sprue, or other malabsorption syndrome, diverticulitis, diverticulosis, or other bowel diagnosis which, in the opinion of the breast surgeon, would contraindicate large doses of dietary fiber or would impair nutrient absorption",
        "  Current, regular (more than once weekly) use of prescription blood-thinning agents including coumadin, heparin and heparin related drugs, clopidogrel bisulfate"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Expression of Estrogen Receptor (ER-beta)",
        "  Mean percentage of cells expressing estrogen receptor (ER-beta)",
        "  Time frame: Biopsy/Week 1 and Surgical Resection/Week 2",
        "Results 1: ",
        "  Arm/Group Title: Arm A - Flaxseed & Active Anastrazole",
        "  Arm/Group Description: 25 mg flaxseed per day and 1 mg anastrozole pill per day",
        "  Anastrozole: 1 mg per day",
        "  flaxseed: 25 g per day ground",
        "  Overall Number of Participants Analyzed: 7",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: percentage of cells  Biopsy: 7 participants",
        "  67.1         (17.0)",
        "Surgical resection: 7 participants",
        "  45.7         (28.8)",
        "Results 2: ",
        "  Arm/Group Title: Arm B - Flaxseed",
        "  Arm/Group Description: Flaxseed 25 mg per day and 1 placebo pill per day",
        "  flaxseed: 25 g per day ground",
        "  Overall Number of Participants Analyzed: 6",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: percentage of cells  Biopsy: 6 participants",
        "  63.3         (10.3)",
        "Surgical resection: 6 participants",
        "  56.7         (23.4)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 0/7 (0.00%)",
        "  Breast haematoma  0/7 (0.00%)",
        "Adverse Events 2:",
        "  Total: 0/7 (0.00%)",
        "  Breast haematoma  0/7 (0.00%)"
    ]
}